<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">As summarized in this review, several gene-based therapies are being tested in clinical trials and numerous more are in the pipeline. These are exciting times. However, the process of bringing a drug into the clinic is cumbersome [
 <xref ref-type="bibr" rid="CR90">90</xref>]. Pharmaceutical Research and Manufacturers of America (PhRMA) estimate that for every 5000 to 10,000 compounds screened, only five enter human clinical trials, only one is approved by the Food and Drug Administration, and only two in ten drugs generate enough revenue to recoup their research and development costs [
 <xref ref-type="bibr" rid="CR91">91</xref>]. Thus, setbacks are expected.
</p>
